Soleus Capital is a healthcare investment firm that is primarily focused on the innovative areas of life sciences, including biotech and medtech.
Investment Stage: Series B
Portfolio 2
| Date | Name | Website | Total Raised | Location |
| 08.01.2026 | Parabilis ... | parabilis.com | $305M | United Sta... |
| 11.07.2023 | @Septerna_... | septerna.com | $290M | United Sta... |
Mentions in press and media 13
| Date | Title | Description |
| 11.01.2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| 08.01.2026 | Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform | Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ... |
| 08.01.2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing. The round was co-led by RA Capital Management, Fidelity Ma... |
| 08.01.2026 | Parabilis rockets ahead with $305M series F to 'upend the status quo' with tumor drug | Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug. The funds come from a smorgasbord of existin... |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 01.10.2025 | Star Therapeutics Raises $125M in Series D Financing | Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding. The round was co-led by Sanofi Ventures and Vi... |
| 29.05.2025 | Pillar Biosciences Secures $34.5 Million to Propel Decision Medicine Forward | Pillar Biosciences is on the rise. The Natik, Massachusetts-based company has secured $34.5 million in funding. This infusion comes from a mix of strategic investors, including Illumina and Soleus Capital. The goal? To enhance their Decisio... |
| 29.05.2025 | Pillar Biosciences: $34.5 Million Raised For Decision Medicine Platform | Pillar Biosciences, a leader in Decision Medicine, announced they have finalized $34.5 million in funding, including a strategic investment from Illumina, structured financing from Soleus Capital, and investments from existing investors. Ho... |
| 24.02.2025 | OrganOx Closes $142M Equity Financing | OrganOx, an Oxford, UK-based organ medical technology company, raised $142M in equity funding. The round was led by new investor HealthQuest Capital with participation from existing investors BGF and Lauxera Capital Partners, along with add... |
| 19.02.2025 | Abcuro: $200 Million (Series C) Raised For Advancing Medicine In Development For Inclusion Body Myositis | Abcuro – a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells – announced the closing of a $200 million Series C financing led by New... |
Show more